|
Match
|
Document |
Document Title |
|
|
US20090317419 |
Tetramers
The present invention relates, in general to human immunodeficiency virus (HIV), and, in particular, to B cell tetramers and to methods of using same for diagnosis, disease monitoring and vaccine...
|
|
|
US20090317418 |
VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS
The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope...
|
|
|
US20090252754 |
Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses
Tat, when used in a vaccine, causes MHC-I to expose subdominant epitopes present within an antigen, thereby enabling an optimal immune response to be generated, within an individual, against the...
|
|
|
US20090246217 |
Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity
In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including...
|
|
|
US20090238841 |
HIV VACCINE FORMULATIONS
Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a...
|
|
|
US20090220536 |
HIV vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-HIV-1 antibodies against the membrane proximal domain of HIV GP41
This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of...
|
|
|
US20090220537 |
VACCINE DELIVERY SYSTEM
An isolated protein comprising a hepatitis B surface antigen (HBsAg) amino acid sequence, and encoding nucleic acid, are provided wherein one or more immunogenic T cell epitopes of the HBsAg are...
|
|
|
US20090214583 |
Epitope-enhancement of a human cd4 hiv epitope
Virus-specific CD4 + T cell help and CD8 + cytotoxic T cell responses are critical for the maintenance of effective immunity in chronic viral infections. The importance of the CD4 + T cells has...
|
|
|
US20090191235 |
CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS AND TRIGGERING HIV-1 ENVELOPE TO REVEAL CRYPTIC V3-LOOP EPITOPES
Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and...
|
|
|
US20090162390 |
Molecular Scaffolds for HIV-1 Immunogens
Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These...
|
|
|
US20090136533 |
POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency...
|
|
|
US20090117141 |
HIV VACCINE COMPOSITION
An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition...
|
|
|
US20090110690 |
Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens
The present disclosure relates to stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, to crystalline forms of the stabilized...
|
|
|
US20090092628 |
Conserved-element vaccines and methods for designing conserved-element vaccines
Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (“CEVac”) is a...
|
|
|
US20090053291 |
FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative...
|
|
|
US20080279879 |
INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed....
|
|
|
US20080267989 |
Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
Recombinant HBsAg-gp120 has been used to present approximately amino acids 1-500 gp120. However, this presentation of gp120 in this form has not successfully been used to produce neutralizing...
|
|
|
US20080220008 |
Mutated Hiv Nef For Modulating Immunity
Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.
|
|
|
US20080187554 |
Process for producing stable HIV Th-CTL peptides
A process for producing a stable formulation of hydrophobic HIV Th/CTL peptides first requires the preparation of a formulation buffer containing 12.5 mM succinic acid and 3% mannitol, and...
|
|
|
US20080160089 |
Vaccine delivery compositions and methods of use
The present invention provides synthetic vaccines against a variety of pathogenic organisms and tumor cells in humans and other mammals based on biodegradable polymers containing polyester amide...
|
|
|
US20080131451 |
Epitope escape mutations
The present invention provides methods for predicting epitope escape mutations arising during the course of HIV disease using an algorithm that predicts the difficulty with which and the manner in...
|
|
|
US20080124352 |
Methods to bypass CD4+
cells in the induction of an immune response
Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses,...
|
|
|
US20080118526 |
Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof
Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further,...
|
|
|
US20080095791 |
Recombinant HIV-1 gp120 Immunogen with Three Different V3 Loops from Viruses of Different Clades
A novel immunogenic HIV-1 Env, particularly gp120, DNA construct is disclosed in which either the V1/V2 loop and the V4 loop, or all three variable loops, including V3, are replaced with a V3...
|
|
|
US20080089902 |
FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative...
|
|
|
US20080089901 |
HIVCON: AN HIV IMMUNOGEN AND USES THEREOF
The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins....
|
|
|
US20080063656 |
Adenoviral Vector Compositions
Applicants disclose herein novel methods, vectors, and vector compositions for improving the efficiency of adenoviral vectors in the delivery and expression of heterologous nucleic acid encoding a...
|
|
|
US20080038286 |
Glycosylated polypeptides produced in yeast mutants and methods of use thereof
The invention provides various high mannose glycosylated polypeptides that are useful in a vaccine formulations. The invention also provides methods for making such glycosylated polypeptides and...
|